SA4Ag vaccine mid dose

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Staphylococcal Infections

Phase 1

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

CompletedNCT01364571

PfizerStaphylococcal Infections

Start: 2011-08-31End: 2013-01-31Updated: 2019-03-04

Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years

CompletedNCT01643941

PfizerStaphylococcal Infections

Start: 2012-08-31End: 2014-03-31Updated: 2019-03-04

Related Papers

Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag)

Open Forum Infectious Diseases2019-12-2420 citations

Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study

Vaccine2016-12-0162 citations

Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial

Vaccine2016-11-1753 citations